Amifampridine

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 453 publications

Longitudinal overview of symptomatic and immunosuppressive drugs in LEMS.

Longitudinal overview of symptomatic and immunosuppressive drugs in LEMS.

Journal: Journal of neuromuscular diseases
Published: August 17, 2026

HSR26-256: Real-World Evidence of Predictors of Time to Amifampridine Discontinuation and Survival in Patients With Cancer-Associated and Non-Cancer-Associated Lambert-Eaton Myasthenic Syndrome in the United States.

HSR26-256: Real-World Evidence of Predictors of Time to Amifampridine Discontinuation and Survival in Patients With Cancer-Associated and Non-Cancer-Associated Lambert-Eaton Myasthenic Syndrome in the United States.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: April 16, 2026

Efficacy and Safety of Amifampridine in Myasthenia Gravis: A Randomized, Double-Blind, Placebo-Controlled Crossover Trial.

Efficacy and Safety of Amifampridine in Myasthenia Gravis: A Randomized, Double-Blind, Placebo-Controlled Crossover Trial.

Journal: Neurology
Published: April 07, 2026

HSR26-256: Real-World Evidence of Predictors of Time to Amifampridine Discontinuation and Survival in Patients With Cancer-Associated and Non-Cancer-Associated Lambert-Eaton Myasthenic Syndrome in the United States.

HSR26-256: Real-World Evidence of Predictors of Time to Amifampridine Discontinuation and Survival in Patients With Cancer-Associated and Non-Cancer-Associated Lambert-Eaton Myasthenic Syndrome in the United States.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: March 30, 2026

Clinical characteristics, cerebellar MR spectroscopy and response to 3,4-diaminopyridine in spinocerebellar ataxia 27B: the Sheffield Ataxia Centre experience.

Clinical characteristics, cerebellar MR spectroscopy and response to 3,4-diaminopyridine in spinocerebellar ataxia 27B: the Sheffield Ataxia Centre experience.

Journal: Journal of neurology
Published: August 11, 2025

PharmVar GeneFocus: NAT2-Genetic Variation and Updated Nomenclature.

PharmVar GeneFocus: NAT2-Genetic Variation and Updated Nomenclature.

Journal: Clinical pharmacology and therapeutics
Published: July 30, 2025

Lambert Eaton Myasthenic Syndrome.

Lambert Eaton Myasthenic Syndrome.

Journal: International review of neurobiology
Published: July 17, 2025

Review of Congenital Myasthenic Syndrome Caused by Pathogenic Variants in GFPT1.

Review of Congenital Myasthenic Syndrome Caused by Pathogenic Variants in GFPT1.

Journal: Muscle & nerve
Published: July 17, 2025

Epidemiological analysis of Lambert-Eaton myasthenic syndrome in Türkiye: insights from a nationwide electronic health database.

Epidemiological analysis of Lambert-Eaton myasthenic syndrome in Türkiye: insights from a nationwide electronic health database.

Journal: Frontiers in neurology
Published: July 16, 2025

The recognition, physiology, and treatment of Lambert-Eaton myasthenic syndrome.

The recognition, physiology, and treatment of Lambert-Eaton myasthenic syndrome.

Journal: Disease-a-month : DM
Published: June 21, 2025

Long-term Efficacy and Safety of Amifampridine Phosphate (Firdapse®) in Japanese Patients with Lambert-Eaton Myasthenic Syndrome (LMS-005 Study).

Long-term Efficacy and Safety of Amifampridine Phosphate (Firdapse®) in Japanese Patients with Lambert-Eaton Myasthenic Syndrome (LMS-005 Study).

Journal: Internal medicine (Tokyo, Japan)
Published: June 18, 2025

The impact of experimental variables in twitch tension recording on triphasic action of phospholipase A2 neurotoxins at the neuromuscular junction and acetylcholine release.

The impact of experimental variables in twitch tension recording on triphasic action of phospholipase A2 neurotoxins at the neuromuscular junction and acetylcholine release.

Journal: Toxicon : official journal of the International Society on Toxinology
Published: June 05, 2025
Showing 1-12 of 453

Last Updated: 09/26/2026